ArticleChinese medicine2025
Huang-Lian-Jie-Du decoction alleviates cognitive impairment in periodontitis rats through restoring microbiota-gut-brain axis and inhibiting neuroinflammation via TLR4/NF-κB pathway.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHuang-Lian-Jie-Du decoction (HLJDD), a typical formulation for heat clearance and detoxification, shows therapeutic potential for oral diseases and cognitive impairment. Nevertheless, the mechanism by which HLJDD influences periodontitis-induced cognitive impairment via the microbiota-gut-brain axis remains unknown. AIM OF THE STUDY: We investigated HLJDD's neuroprotective effects in periodontitis rats, focusing on its modulation of the microbiota-gut-brain axis and underlying molecular mechanisms. MATERIALS AND
methodsChemical profiling of HLJDD was performed via UHPLC-Q-Exactive Orbitrap HRMS. Periodontitis was induced in SD rats using ligatures and Porphyromonas gingivalis for 2 weeks, followed by 8-week treatments with HLJDD (0.75/1.5/3 g/kg/day), doxycycline (10 mg/kg/day), or vehicle. Alveolar bone loss was assessed via micro-CT, while cognitive function was assessed via the Morris water maze (MWM). Hippocampal and colon pathology was analyzed via H&E, Nissl staining, and immunohistochemistry. The composition of gut microbiota was analyzed by 16S rDNA sequencing. The tight junction proteins in hippocampus and colon were examined by RT- qPCR and immunofluorescence (IF). Inflammatory cytokine levels in intestinal and hippocampus tissue and serum were quantified by ELISA. Network pharmacology predicted potential mechanisms, and Western blotting assessed TLR4/NF-κB pathway proteins.
resultsHLJDD contained 94 bioactive compounds and significantly attenuated alveolar bone loss, improved cognitive function, and reduced neuronal damage and Aβ deposition. It restored gut microbiota homeostasis, enhanced intestinal and blood-brain barrier integrity, and suppressed neuroinflammation by modulating pro- and anti-inflammatory cytokines. Mechanistically, HLJDD inhibited TLR4/NF-κB signaling, suggesting its therapeutic potential in periodontitis-related cognitive impairment.
conclusionHLJDD ameliorates cognitive impairment in periodontitis by modulating the microbiota-gut-brain axis, reducing neuroinflammation, and inhibiting TLR4/NF-κB activation. These findings support its potential as a novel therapeutic strategy for periodontitis-associated cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.